

3rd NCI Symposium on Cancer Health Disparities

April 16 - 17, 2020

Supported by CCR Cancer Health Disparities Interest Group

OVERVIEW

AGENDA

REGISTRATION

ABSTRACT

LOCATION

HOTEL & TRAVEL

SECURITY

General Information

For conference-related questions please contact

Julia Lam

ccrconferences@mail.nih.gov

301-846-6957

Location

National Institutes of Health

9000 Rockville Pike
Bethesda, Maryland 20892
Porter Neuroscience (Bldg 35)
Room 610/620/630

[View Website](#)

[ADD TO CALENDAR](#)

[View](#) [Access control](#) [Edit](#) [Delete](#) [Clone](#)

Abstract Submission

Abstracts for consideration are welcome and due by January 31st by 11:59PM.

The Organizing Committee encourages you to submit abstracts for poster presentation of your latest work. Your abstract should be submitted at the same time as your registration. Abstracts will be included in the meeting materials. Highly rated abstracts will be selected for oral presentations.

NOTE: Submission of an abstract DOES NOT register you for the meeting.

Guidelines for Abstract Submission: Please follow the guidelines below for preparing your abstract. Abstracts that do not comply with the stated specifications may be returned for editing.

1. Please use Microsoft Word for PC or Mac to type your abstract. Be sure to save the abstract on your computer prior to uploading.
2. File name should have the AUTHORS last name listed (example: 2020-Abstract-SMITH)
3. Text should be single-spaced, 10-point Times New Roman font with 1-inch margins.
4. The body of the abstract must not exceed more than 400 words.
5. The first letter of each word in your TITLE should be capitalized.
6. List the authors' first and last names and affiliations in both uppercase and lowercase letters, directly below the title.
7. Underline the name of the presenting author
8. Identify the corresponding affiliation and location for each author.
9. Skip one line between the listing of authors and the text of your abstract.

Example:

Molecular Remissions of Hairy Cell Leukemia with Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox Correlate with Improved Complete Remission Duration in Phase 1 and 3 Testing.

Robert J. Kreitman¹, Daniel Gorelik¹, Maryalice Stetler-Stevenson², Constance Yuan², Mark Raffeld², Liqiang Xi², Mark Sokolsky¹, Hong Zhou¹, Nai Shun Yao³, Shannon Marshall³, Katherine Potocka¹, Erin Fykes¹, Evgeny Arons¹ and Ira Pastan¹.

¹LMB

²LP, CCR, NCI

³MedImmune, Gaithersburg, Maryland

Please direct any questions regarding issues relevant to abstract submissions to: ccrconferences@mail.nih.gov

OMB No.: 0925-0740

Expiration Date: 07/31/2022

Public reporting burden for this collection of information is estimated to average 5 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to: NIH, Project Clearance Branch, 8705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0740). Do not return the completed form to this address.